On Mar. 9, 2020, Innovation Pharmaceuticals announced it was notified by one of the 12 Regional Biocontainment Labs in the U.S. that it had received shipment of Brilacidin, the Company’s defensin mimetic drug candidate, for testing against SARS-CoV-2, the specific coronavirus responsible for COVID-19.

Brilacidin was immediately placed into queue and testing began the week of Mar. 16.